Literature DB >> 26224928

Search of ligands suitable for 212Pb/212Bi in vivo generators.

Barbara Bartoś1, Krzysztof Lyczko1, Agata Kasperek1, Seweryn Krajewski1, Aleksander Bilewicz1.   

Abstract

The short half-life of 212Bi and 213Bi limits the application of these radionuclides in α radionuclide therapy. The labeling of biomolecules with 212Pb (mother nuclide of 212Bi) instead of 212Bi or 213Bi has the advantage of obtaining a conjugate with a half-life of 10.6 h, compared with of 60 min for 212Bi or 46 min for 213Bi. Previous attempts to prepare a potential in vivo generator with 212Pb complexed by the DOTA chelator failed, because about 36 % of Bi was reported to escape as a result of the radioactive decay [Formula: see text]. Herein, we report studies on the stability of the 212Pb complexes with eight selected polydentate ligands, which demonstrate high affinity for 3+ metal cations. From the ligand studied DOTP and BAPTA show a sufficient 212Pb labeling yields but only 212Pb-DOTP complex is stable in isotonic solution of sodium chloride making this way radioactivity level of released 212Bi is below the limit of detection. It should be emphasized that the DOTP complex is stable only in the case when the concentration of free DOTP exceeds 10-4 M.

Entities:  

Keywords:  212Bi; 212Pb; In vivo generator; Polyaminipolycarboxylate ligands

Year:  2012        PMID: 26224928      PMCID: PMC4513904          DOI: 10.1007/s10967-012-2238-4

Source DB:  PubMed          Journal:  J Radioanal Nucl Chem        ISSN: 0236-5731            Impact factor:   1.371


  7 in total

1.  Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.

Authors:  Diane E Milenic; Kayhan Garmestani; Erik D Brady; Kwamena E Baidoo; Paul S Albert; Karen J Wong; Joseph Flynn; Martin W Brechbiel
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

2.  Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.

Authors:  Fu-Min Su; Paul Beaumier; Don Axworthy; Robert Atcher; Alan Fritzberg
Journal:  Nucl Med Biol       Date:  2005-10       Impact factor: 2.408

3.  Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.

Authors:  Diane E Milenic; Kayhan Garmestani; Erik D Brady; Paul S Albert; Dangshe Ma; Alia Abdulla; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2005-10       Impact factor: 3.099

4.  Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.

Authors:  D Cordier; F Forrer; F Bruchertseifer; A Morgenstern; C Apostolidis; S Good; J Müller-Brand; H Mäcke; J C Reubi; A Merlo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-16       Impact factor: 9.236

5.  Towards translation of 212Pb as a clinical therapeutic; getting the lead in!

Authors:  Kwon Yong; Martin W Brechbiel
Journal:  Dalton Trans       Date:  2011-03-04       Impact factor: 4.390

6.  Melanoma therapy via peptide-targeted {alpha}-radiation.

Authors:  Yubin Miao; Mark Hylarides; Darrell R Fisher; Tiffani Shelton; Herbert Moore; Dennis W Wester; Alan R Fritzberg; Christopher T Winkelmann; Timothy Hoffman; Thomas P Quinn
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

7.  Nonuniformity of tumor dose in radioimmunotherapy.

Authors:  J L Humm; L M Cobb
Journal:  J Nucl Med       Date:  1990-01       Impact factor: 10.057

  7 in total
  5 in total

Review 1.  In Vivo Radionuclide Generators for Diagnostics and Therapy.

Authors:  Patricia E Edem; Jesper Fonslet; Andreas Kjær; Matthias Herth; Gregory Severin
Journal:  Bioinorg Chem Appl       Date:  2016-12-12       Impact factor: 7.778

2.  In situ Generated <sup>212</sup>Pb-PSMA Ligand in a <sup>224</sup>Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells.

Authors:  Vilde Y Stenberg; Asta Juzeniene; Øyvind S Bruland; Roy H Larsen
Journal:  Curr Radiopharm       Date:  2020

3.  Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair.

Authors:  Brooke L McNeil; Andrew K H Robertson; Winnie Fu; Hua Yang; Cornelia Hoehr; Caterina F Ramogida; Paul Schaffer
Journal:  EJNMMI Radiopharm Chem       Date:  2021-02-01

Review 4.  Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.

Authors:  Bryce J B Nelson; Jan D Andersson; Frank Wuest
Journal:  Pharmaceutics       Date:  2020-12-31       Impact factor: 6.321

Review 5.  212Pb: Production Approaches and Targeted Therapy Applications.

Authors:  Konstantin V Kokov; Bayirta V Egorova; Marina N German; Ilya D Klabukov; Michael E Krasheninnikov; Antonius A Larkin-Kondrov; Kseniya A Makoveeva; Michael V Ovchinnikov; Maria V Sidorova; Dmitry Y Chuvilin
Journal:  Pharmaceutics       Date:  2022-01-13       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.